Dr. Reddys Laboratories Ltd 2024 IR
The report highlights Dr. Reddy's Laboratories Limited's performance for the fiscal year 2023-2024, marking its 40th year of serving patients. The company achieved a record revenue of ₹279.2 billion, representing 14% growth, and reached an estimated 704 million patients. Key achievements include entering the Dow Jones Sustainability World Index and launching its first digital therapeutics product, Nerivio, in India. Additionally, the company increased its renewable power share to 56% and achieved 48% carbon neutrality in its direct operations.
Company: Dr. Reddys Laboratories Ltd
Sector: Health Care
Country: India
Year: 2024
Type: IR
Pages: 235
Back to company
Dr. Reddys Laboratories Ltd
Integrated Annual Report
The report highlights Dr. Reddy's Laboratories Limited's performance for the fiscal year 2023-2024, marking its 40th year of serving patients. The company achieved a record revenue of ₹279.2 billion, representing 14% growth, and reached an estimated 704 million patients. Key achievements include entering the Dow Jones Sustainability World Index and launching its first digital therapeutics product, Nerivio, in India. Additionally, the company increased its renewable power share to 56% and achieved 48% carbon neutrality in its direct operations.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Apr 1, 2023 - Mar 31, 2024
Fiscal Year
2024
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees